Granted Patent
B2
US 12,351,560 · App. 18/190,843 · Granted Jul 8, 2025
Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Procedures for inhibiting hormone receptor activation include administering to a subject in need of hormone receptor inhibition a compound having a chemical structure of a molecule that, when docked in the PPIase pocket, could disrupt proline-rich loop conformation and interactions. Procedures for treating prostate cancer or breast cancer include administering to a subject having prostate cancer or breast cancer a compound having a chemical structure of a molecule that, when docked in the PPIase pocket, could disrupt proline-rich loop conformation and interactions.
Claims (10)
1. A method of inhibiting hormone receptor activation, comprising administering to a subject in need of hormone receptor inhibition a compound having a chemical structure of Formula II
2. The method of claim 1 , wherein the hormone receptor is an androgen receptor.
3. The method of claim 1 , wherein the subject has hyperplasia.
4. The method of claim 1 , wherein the subject has neoplasia.
5. The method of claim 1 , wherein the subject has prostate cancer or breast cancer.
6. The method of claim 1 , further comprising administering chemotherapy or radiation treatments.
7. A method of treating prostate cancer or breast cancer comprising administering to a subject having prostate cancer or breast cancer a compound having a chemical structure of Formula II
8. The method of claim 7 , further comprising administering chemotherapy or radiation treatments.
9. The method of claim 7 , wherein the compound when docked in a PPIase pocket disrupts proline-rich loop conformation and interactions.
10. The method of claim 9 , wherein the PPIase pocket includes an FKBP52 PPIase pocket.
Assignments (3)
CONFIRMATORY LICENSE
Recorded Sep 11, 2024
From: UNIVERSITY OF TEXAS EL PASO
To: UNITED STATES GOVERNMENT
Reel/Frame 068926/0808 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 7, 2023
From: CHERKASOV, ARTEM; BAN, FUQIANG
To: THE UNIVERSITY OF BRITISH COLUMBIA
Reel/Frame 065481/0117 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 28, 2023
From: COX, MARC
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 065060/0333 →
Continuity (3)
Provisional Application
62963873
· Jan 21, 2020
References Cited (70)
Alam, et al., “3D-QSAR, Docking, ADME/Tox studies on Flavone analogs reveal anticancer activity through Tankyrase inhibition,” Scientific Reports 2019,9.
[cited by applicant]
Anderson, “The process of structure-based drug design,” Chemistry & biology 2003, 10 (9), 787-797.
[cited by applicant]
Araujo, et al., “Computational studies of TGF-beta RI (ALK-5) inhibitors: Analysis of the binding interactions between ligand-receptor using 2D and 3D techniques,” European Journal of Pharmaceutical Sciences 2013, 49 (4…
[cited by applicant]
Awale, et al., “Chemical Space: Big Data Challenge for Molecular Diversity,” Chimia 2017, 71 (10), 661-666.
[cited by applicant]
Bonomo, et al., “Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors,” Scientific Reports 2016, 6.
[cited by applicant]
Bracher, et al., “Crystal Structures of the Free and Ligand-Bound FK1-FK2 Domain Segment of FKBP52 Reveal a Flexible Inter-Domain Hinge,” Journal of Molecular Biology 2013, 425 (22), 4134-4144.
[cited by applicant]
Caballero, 3D-QSAR (CoMFA and CoMSIA) and pharmacophore (GALAHAD) studies on the differential inhibition of aldose reductase by flavonoid compounds. Journal of Molecular Graphics & Modelling 2010, 29 (3), 363-371.
[cited by applicant]
Capecchi, et al., “PubChem and ChEMBL beyond Lipinski,” Molecular Informatics 2019, 38 (5).
[cited by applicant]
Cavasotto, et al., “Quantum Chemical Approaches in Structure-Based Virtual Screening and Lead Optimization,” Frontiers in Chemistry 2018, 6.
[cited by applicant]
Chatterjee, et al., “ImmtorLig_DB: repertoire of virtually screened small molecules against immune receptors to bolster host immunity,” Scientific Reports 2019, 9.
[cited by applicant]
Cheng, et al., “Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review,” Aaps Journal 2012,14 (1), 133-141.
[cited by applicant]
Cherkasov, et al., “QSAR Modeling: Where Have You Been? Where Are You Going To?,” Journal of Medicinal Chemistry 2014, 57 (12), 4977-5010.
[cited by applicant]
Chirico, et al., “Real External Predictivity of QSAR Models: How to Evaluate It? Comparison of Different Validation Criteria and Proposal of Using the Concordance Correlation Coefficient,” Journal of Chemical Informatio…
[cited by applicant]
Cramer, et al., “Comparative molecular field analysis (CoMFA),” 1. Effect of shape on binding of steroids to carrier proteins. Journalof the American Chemical Society 1988, 110 (18), 5959-5967.
[cited by applicant]
De Angelo, et al., “Studies on the Dual Activity of EGFR and HER-2 Inhibitors Using Structure-Based Drug Design Techniques,” International journal of molecular sciences 2018, 19 (12), 3728.
[cited by applicant]
De Benedetti, et al., “Computational quantum chemistry and adaptive ligand modeling in mechanistic QSAR,” Drug Discovery Today 2010, 15 (19-20), 859-866.
[cited by applicant]
De Leon, et al., “Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells,” Proceedings of the National Academy of Sciences of the United States o…
[cited by applicant]
Dey, et al., “A machine learning based intrusion detection scheme for data fusion in mobile clouds involving heterogeneous client networks,” Information Fusion 2019, 49, 205-215.
[cited by applicant]
Fang, et al., “3DQSAR and docking studies of flavonoids as potent
[cited by applicant]
Feng, et al., “Combined pharmacophore-guided 3D-QSAR, molecular docking and molecular dynamics studies for evodiamine analogs as DNA topoisomerase I inhibitors,” Journal of the Taiwan Institute of Chemical Engineers 201…
[cited by applicant]
Gaudio, et al., “Proposition, validation and analysis of QSAR models,” Química Nov. 2001, 24 (5), 658-671.
[cited by applicant]
Gopalakrishnan, et al., “Exploration of Pipecolate Sulfonamides as Binders of the FK506-Binding Proteins 51 and 52,” Journal of Medicinal Chemistry 2012, 55 (9), 4123-4131.
[cited by applicant]
Gramatica, et al., “Principles of QSAR models validation: internal and external,” QSAR & combinatorial science 2007, 26 (5), 694-701.
[cited by applicant]
Guo, et al., “In silico rational design and virtual screening of antixoidant tripeptides based on 3D-QSAR modeling,” Journal of Molecular Structure 2019, 1193, 223-230.
[cited by applicant]
Hong, et al., “Elevated FKBP52 expression indicates a poor outcome in patients with breast cancer,” Oncology Letters 2017, 14 (5), 5379-5385.
[cited by applicant]
Huang, et al., “QSAR Pharmacophore-based Virtual Screening, CoMFA and CoMSIA Modeling and Molecular Docking towards Identifying Lead Compounds for Breast Cancer ProteaseInhibitors,” British Journal of Pharmaceutical Res…
[cited by applicant]
Irwin, et al., “Zinc: A Free Tool to Discover Chemistry for Biology,” Journal of Chemical Information and Modeling 2012, 52 (7), 1757-1768.
[cited by applicant]
Kaushik, et al., “Ligand-Based Approach for In-silico Drug Designing,” Bioinformatics Techniques for Drug Discovery: Applications for Complex Diseases 2018, 11-19.
[cited by applicant]
Kubinyi, “QSAR and 3D QSAR in drug design Part 2: applications and problems,” Drug Discovery Today 1997, 2 (12), 538-546.
[cited by applicant]
Kubinyi, et al., “3D QSAR in Drug Design: vol. 2: Ligand-Protein Interactions and Molecular Similarity,” Springer: 1998; vol. 2.
[cited by applicant]
Kumar, et al., “E-pharmacophore modelling, virtual screening, molecular dynamics simulations and in-silico ADME analysis for identification of potential E6 inhibitors against cervical cancer,” Journal of Molecular Struc…
[cited by applicant]
Kumar, et al., “Virtual screening strategies: Recent advances in the identification and design of anti-cancer agents,” Methods 2015, 71, 64-70.
[cited by applicant]
Langer, et al., “Virtual screening an effective tool for lead structure discovery,” Current pharmaceutical design 2001, 7 (7), 509-527.
[cited by applicant]
Leal, et al., “Hologram QSAR Models of a Series of 6-Arylquinazolin-4-Amine Inhibitors of a New Alzheimer's Disease Target: Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase-1A Enzyme,” International Journal of…
[cited by applicant]
Li, et al., “Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer,” Molecular Cancer Therapeutics 2013, 12 (11), 2425-2435.
[cited by applicant]
Li, et al., “Discovery of Small-Molecule Inhibitors Selectively Targeting the DNA-Binding Domain of the Human Androgen Receptor,” J Med Chem 2014, 57 (15), 6458-6467.
[cited by applicant]
Li, et al., “New molecular insights into the tyrosyl-tRNA synthase inhibitors: CoMFA, CoMSIA analyses and molecular docking studies,” Scientific Reports 2017, 7.
[cited by applicant]
Li, et al., “Structure of the N-terminal domain of human FKBP52,” Acta Crystallographica Section D-Biological Crystallography 2003, 59, 16-22.
[cited by applicant]
Lionta, et al., “Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances,” Current Topics in Medicinal Chemistry 2014, 14 (16), 1923-1938.
[cited by applicant]
Llanos, et al., “Computational approach to the history of chemical reactivity: Exploring Reaxys database,” Abstracts of Papers of the American Chemical Society 2017, 254.
[cited by applicant]
Mahdi, et al., “Similarity Search Techniques in Exploratory Search: A Review”, IEEE-Region-10 Conference (IEEE TENCON), IEEE Reg 10, South Korea, Oct. 28-31; Ieee: IEEE Reg 10, South Korea, 2018; pp. 2193-2198.
[cited by applicant]
Maltarollo, et al., “Advanced QSAR Studies on PPAR delta Ligands Related to Metabolic Diseases,” Journal of the Brazilian Chemical Society 2012, 23 (1), 85-U421.
[cited by applicant]
Nandy, et al., “Exploring molecular fingerprints of selective PPAR delta agonists through comparative and validated chemometric techniques,” Sar and Qsar in Environmental Research 2015, 26 (5), 363-382.
[cited by applicant]
Netzeva, et al., “Current status of methods for defining the applicability domain of (quantitative) structure activity relationships—The report and recommendations of ECVAM Workshop 52,” Atla-Alternatives to Laboratory …
[cited by applicant]
Nunes, et al., “Chemoface: a Novel Free User-Friendly Interface for Chemometrics,” Journal of the Brazilian Chemical Society 2012, 23 (11), 2003-2010.
[cited by applicant]
O'Boyle, et al., “PubChem as a biologics database,” Abstracts of Papers of the American Chemical Society 2017, 254.
[cited by applicant]
O'Boyle, et al., “Testing Assumptions and Hypotheses for Rescoring Success in Protein-Ligand Docking,” Journal of Chemical Information and Modeling 2009, 49 (8), 1871-1878.
[cited by applicant]
Ou-Yang, et al., “Computational drug discovery,” Acta Pharmacologica Sinica 2012, 33 (9), 1131-1140.
[cited by applicant]
Pick, et al., “Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP),” Bioorg. Med. Chem. 2011, 19 (6), 2090-2102.
[cited by applicant]
Saikia, et al., “Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective,” Current Drug Targets 2019, 20 (5), 501-521.
[cited by applicant]
Salum, et al., “Structure-Based Approach for the Study of Estrogen Receptor Binding Affinity and Subtype Selectivity,” Journal of Chemical Information and Modeling 2008, 48 (11), 2243-2253.
[cited by applicant]
Shahbaaz, et al., “Designing novel possible kinase inhibitor derivatives as therapeutics against
[cited by applicant]
Spena, et al., “Virtual screening identifies a PIN1 inhibitor with possible antiovarian cancer effects,” Journal of Cellular Physiology 2019, 234 (9), 15708-15716.
[cited by applicant]
Stope, et al., “Re: Targeting the Regulation of Androgen Receptor Signaling by the Heat Shock Protein 90 Cochaperone FKBP52 in Prostate Cancer Cells,” European Urology 2012, 62 (5), 931-932.
[cited by applicant]
Svensson, et al., “Virtual Screening Data Fusion Using Both Structure- and Ligand-Based Methods,” Journal of Chemical Information and Modeling 2012, 52 (1), 225-232.
[cited by applicant]
Tan, et al., “Comprehensive Modeling and Discovery of Mebendazole as a Novel TRAF2-and NCK-interacting Kinase Inhibitor,” Scientific Reports 2016, 6.
[cited by applicant]
Tong, et al., “Molecular Virtual Screening Studies of Herbicidal Sulfonylurea Analogues Using Molecular Docking and Topomer CoMFA Research,” Journal of Structural Chemistry 2019, 60 (2), 210-218.
[cited by applicant]
Vora, et al., “Structure based virtual screening, 3D-QSAR, molecular dynamics and ADMET studies for selection of natural inhibitors against structural and non-structural targets of Chikungunya,” Journal of Biomolecular …
[cited by applicant]
Warren, et al., “Essential considerations for using protein-ligand structures in drug discovery,” Drug Discovery Today 2012, 17 (23-24), 1270-1281.
[cited by applicant]
Xie, et al., “Early development of GMC1, a novel molecule targeting FKBP52 for the treatment of hormone-refractory prostate cancer” Cancer Research 2017, 77.
[cited by applicant]
Xie, et al., “Pharmacophore modeling, virtual screening, and 3D-QSAR studies on a series of non-steroidal aromatase inhibitors,” Medicinal Chemistry Research 2015, 24 (5), 1901-1915.
[cited by applicant]
Yao, et al., “3DQSAR, molecular docking and molecular dynamics simulations study of 3-pyrimidin-4-yl-oxazolidin-2-one derivatives to explore the structure requirements of mutant IDH1inhibitors,” Journal of Molecular Str…
[cited by applicant]
Yap, et al., “PaDEL-Descriptor: An Open Source Software to Calculate Molecular Descriptors and Fingerprints,” Journal of Computational Chemistry 2011, 32 (7), 1466-1474.
[cited by applicant]
Zhang, et al., “Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors,” Molecules 2018, 23 (11).
[cited by applicant]
Zhang, et al., “Recent In Silico Research in High-Throughput Drug Discovery and Molecular Biochemistry,” Current Topics in Medicinal Chemistry 2019, 19 (2), 103-104.
[cited by applicant]
Zhang, et al., “Virtual Screening, Biological Evaluation, and 3D-QSAR Studies of New HIV-1 Entry Inhibitors That Function via the CD4 Primary Receptor,” Molecules 2018, 23 (11).
[cited by applicant]
Zhou, et al., “Discovery of Novel Androgen Receptor Ligands by Structure-based Virtual Screening and Bioassays,” Genomics Proteomics & Bioinformatics 2019, 16 (6), 416-427.
[cited by applicant]
Zhu, et al., “Identifying Potential Dual Inhibitory Candidates for Non-Small Cell Lung Cancer through Molecular Docking, 3D-QSAR Pharmacophore-based Virtual Screening, Comparative Molecular Field and Similarity Indices …
[cited by applicant]